European Journal of Pharmacology 1999-07-01

Inhibition of cardiac inward-rectifier K+ current by terodiline.

SE Jones, Y Kasamaki, T Ogura, LM Shuba, JR McCullough, TF McDonald

Index: Eur. J. Pharmacol. 370(3) , 319-27, (1999)

Full Text: HTML

Abstract

The antispasmodic agent terodiline has cardiotoxic effects that include QT lengthening. To determine whether inhibition of inwardly-rectifying K+ current (I(K1)) might be a factor in the cardiotoxicity, we measured I(K1) in guinea pig ventricular myocytes. Terodiline reduced outward I(K1) with an IC50 of 7 microM; maximal reduction was 60% with 100-300 microM concentration. Inhibition was independent of current direction, and persisted after removal of the drug. Terodiline (3-5 microM) lengthened action potentials in guinea pig papillary muscles by ca. 10%, primarily by slowing phase 3 repolarization; higher concentrations abbreviated the plateau and markedly slowed late repolarization. Terodiline washout provoked an extra lengthening, consistent with persistent inhibition of I(K1) and rapid recovery of net inward plateau current. The results suggest that inhibition of I(K1) is a likely factor in the cardiotoxicity of the drug.


Related Compounds

Related Articles:

Action potentials, contraction, and membrane currents in guinea pig ventricular preparations treated with the antispasmodic agent terodiline.

1999-09-01

[J. Pharmacol. Exp. Ther. 290(3) , 1417-26, (1999)]

Comparison of the effects of NS-21 and terodiline on the QTc interval in dogs.

1998-01-01

[Gen. Pharmacol. 30(1) , 137-42, (1998)]

CYP2D6 and CYP2C19 genotypes of patients with terodiline cardiotoxicity identified through the yellow card system.

2000-07-01

[Br. J. Clin. Pharmacol. 50(1) , 77-80, (2000)]

Pharmacokinetic/pharmacodynamic assessment of the effects of E4031, cisapride, terfenadine and terodiline on monophasic action potential duration in dog.

2001-01-01

[Xenobiotica 31(8-9) , 633-50, (2001)]

In vitro preclinical cardiac assessment of tolterodine and terodiline: multiple factors predict the clinical experience.

2006-11-01

[J. Cardiovasc. Pharmacol. 48(5) , 199-206, (2006)]

More Articles...